{"id":"W4408275933","doi":"10.1038/s41591-025-03572-3","title":"Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University of Texas MD Anderson Cancer Center; National Institutes of Health; Grifols; National Cancer Institute; Gilead Sciences; Servier; Astellas Pharma; Sierra Oncology; Pfizer; Incyte; CTI Biopharma; BeiGene; Bristol-Myers Squibb; Constellation Pharmaceuticals; Agios Pharmaceuticals; Swedish Orphan Biovitrum; MPN Research Foundation; Leukemia and Lymphoma Society; Alexion Pharmaceuticals; Sanofi; MorphoSys; Celgene; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Randomized controlled trial; Internal medicine; Oncology; Pharmacology; Bone marrow","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00116278,0.0005183612,0.002292793,0.0004663319,0.0002130267,0.00002596668,0.0001501683,0.0006234483,0.000398449],"category_scores_gemma":[0.004828567,0.0003227951,0.0005163961,0.0005393403,0.0003788257,0.00007205316,0.00005062537,0.0007982719,0.00001856822],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003155472,"about_ca_system_score_gemma":0.0006025581,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005904623,"about_ca_topic_score_gemma":0.00001732796,"domain_scores_codex":[0.9969105,0.0002138714,0.0009684238,0.0007250192,0.0006477129,0.0005344706],"domain_scores_gemma":[0.9959182,0.002397843,0.0002619795,0.0005149287,0.0005957789,0.0003112747],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8369434,0.001050213,0.00008914793,0.0003886049,0.001125763,0.00006452127,0.0006353281,6.298781e-7,0.001138157,0.02039513,0.1322333,0.00593579],"study_design_scores_gemma":[0.871506,0.003560371,0.000119043,0.001509858,0.002129842,0.00002226641,0.0002620807,0.0002847197,0.01034647,0.001546978,0.1084944,0.0002179266],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6145938,0.05499052,0.004264311,0.2094955,0.01241087,0.04129091,0.000402525,0.0006841848,0.0618674],"genre_scores_gemma":[0.9646684,0.0007191139,0.001928629,0.01320445,0.004585099,0.003990148,0.0007182221,0.0000632275,0.01012271],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3500746,"threshold_uncertainty_score":0.9999224,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01641653940877218,"score_gpt":0.3723830453634038,"score_spread":0.3559665059546316,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}